UPCC 06918:A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors
Enrolling By Invitation
99 years or below
All
1 Location
Brief description of study
We are requesting to rely on WIRB as IRB of record for this study.
This Study has 2 parts. The purpose of the Part 1 is to try to find the best dose of INCB081776 alone for patients who have advanced cancer. The purpose of Part 2 is to find the best dose of INCB081776 when given in combination with nivolumab.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
08 Mar 2023.
Study ID: 829888
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
